Abstract
Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognoses of all malignancies, with a 5-year survival rate <8%.1,2 Suspicious lesions are typically diagnosed via endoscopic ultrasound–guided fine-needle aspiration or endoscopic ultrasound–guided fine-needle biopsy (EUS-FNB).3 Fewer needle passes decreases the risk of postprocedure complications, including pancreatitis and hemorrhage, while allowing additional needle passes to be used for adjuvant tissue testing, such as organoid creation and DNA sequencing.
Original language | English |
---|---|
Pages (from-to) | 845-847 |
Number of pages | 3 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 19 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2021 |
Externally published | Yes |